← Leaderboards
Isabel Lauren Jackson
Humanetics Corporation
$7,555,426
Attributed
$7,853,953
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2016–24$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,311,501 · 5
By mechanism
U19$17,714,446 · 4
R43$597,055 · 1
Top collaborators
- France Carrier4 shared
- Michael D Kaytor2 shared
Most similar at Humanetics Corporation
Same institution · by research overlap
- Michael D Kaytor$2,888,484
Others in their field
Top investigators on “Advanced Development”
- David Heimbrook · Leidos Biomedical Research, Inc.$625,894,719
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$331,630,794
- David H Reitze · University Of Florida$318,606,363
- Albert Lazzarini · California Institute Of Technology$317,303,333
Research focus
Advanced DevelopmentAcuteRadiation CountermeasureRadiation SyndromesMedical CountermeasureMemberDrug KineticsDoseMarylandRadiation InjuriesWhole-Body IrradiationAnimal RuleAnimal ModelNuclear AccidentsSafetyNonhuman PrimateCollaborationsRadiation ExposureNational Institute Of Allergy And Infectious DiseaseRadiation AccidentsPharmacometricsEnsureRandomizedRadiation Sicknesses
Grant awards (20)
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes$2,354,817
U19 · FY2024 · AI
Animal Efficacy and Pharmacometric Modeling Core$763,014
U19 · FY2024 · AI · contact PI
Development of BIO 300 for mitigation and/or treatment of radiation pneumonitis and fibrosis$361,556
U19 · FY2024 · AI · contact PI
Administrative Core$254,340
U19 · FY2024 · AI · contact PI
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes$2,971,749
U19 · FY2023 · AI
Animal Efficacy and Pharmacometric Modeling Core$1,370,626
U19 · FY2023 · AI · contact PI
Development of BIO 300 for mitigation and/or treatment of radiation pneumonitis and fibrosis$384,716
U19 · FY2023 · AI · contact PI
Administrative Core$225,278
U19 · FY2023 · AI · contact PI
Preclinical Evaluation of Radioprotectin-1 for Mitigation of GI-ARS$23,254
U19 · FY2023 · AI
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes$2,438,056
U19 · FY2022 · AI
Animal Efficacy and Pharmacometric Modeling Core$789,988
U19 · FY2022 · AI · contact PI
Development of BIO 300 for mitigation and/or treatment of radiation pneumonitis and fibrosis$374,337
U19 · FY2022 · AI · contact PI
Administrative Core$263,328
U19 · FY2022 · AI · contact PI
Intercollaborative Radiation Countermeasure (INTERACT) Consortium for Advanced Development of Medical Countermeasures to Mitigate/Treat Acute and Delayed Radiation Syndromes$2,669,672
U19 · FY2021 · AI · contact PI
Animal Efficacy and Pharmacometric Modeling Core$994,870
U19 · FY2021 · AI · contact PI
Development of BIO 300 for mitigation and/or treatment of radiation pneumonitis and fibrosis$407,370
U19 · FY2021 · AI · contact PI
Administrative Core$256,350
U19 · FY2021 · AI · contact PI
Animal Efficacy and Pharmacometric Modeling Core$811,125
U19 · FY2020 · AI · contact PI
Development of BIO 300 as a MCM for lethal radiation pneumonitis/fibrosis$298,020
R43 · FY2017 · AI
Development of BIO 300 as a MCM for lethal radiation pneumonitis/fibrosis$299,035
R43 · FY2016 · AI